| Literature DB >> 1869982 |
J M Michelot1, M F Moreau, P G Labarre, J C Madelmont, A J Veyre, J M Papon, D F Parry, J F Bonafous, J Y Boire, G G Desplanches.
Abstract
The synthesis, labeling, and biodistribution of four 125I radiopharmaceuticals designed to localize in melanoma were tested. Uptake in tumors was demonstrated by autoradiography of whole-body sections and quantitated by measurement of radioactivity of selected tissues and tumors using melanoma-bearing mice. N-(2-diethylaminoethyl)-4-iodobenzamide was selected for its highest melanoma uptake: 60 min after IV injection of 6.5% and 4% ID/g, respectively for murine B16 and human melanotic melanoma. Tumor uptake showed the highest values of all analyzed tissues from 6 to 24 hr after injection. High uptake in melanotic tumor tissue with relatively low uptake in blood, muscle, brain, lung, and liver tissue resulted in high tumor/nontumor ratios (at 24 hr for B16, tumor/blood = 37, tumor/brain = 147, tumor/muscle = 95). This agent was compared with iodoamphetamine. Scintigraphic images of the tumor confirmed that external detection of melanoma is possible with this new radiopharmaceutical.Entities:
Mesh：
Substances：
Year: 1991 PMID： 1869982
Source DB: PubMed Journal: J Nucl Med ISSN： 0161-5505 Impact factor: 10.057